A modified comorbidity index for hematopoietic cell transplantation

Area of Science:

• Hematology
• Transplant Medicine
• Biostatistics

Background:

• The HCT-specific comorbidity index (HCT-CI) is used to assess transplant-related risk in allogeneic hematopoietic cell transplant (HCT) recipients.
• Previous validation analysis indicated that the HCT-CI may not effectively segregate patient risk.
• There is a need for improved tools to predict mortality and stratify risk in HCT patients.

Purpose of the Study:

• To develop and evaluate a modified comorbidity index (MCI) with enhanced predictive and discriminating power for mortality in allogeneic HCT recipients.
• To improve upon the existing HCT-specific comorbidity index (HCT-CI) by utilizing hazard ratios (HR) instead of categorical weights for comorbidities.
• To assess the MCI's ability to predict non-relapse mortality (NRM) and overall survival.

Main Methods:

• A cohort of 444 adult allogeneic HCT recipients was used to develop the MCI.
• A pure multiplicative model was employed, replacing categorical comorbidity weights with HRs from a Fine and Gray adjusted regression model.
• The predictive performance of the MCI was compared against the HCT-CI for non-relapse mortality (NRM).

Main Results:

• The modified comorbidity index (MCI) demonstrated improved discrimination for non-relapse mortality (NRM) compared to the HCT-specific comorbidity index (HCT-CI).
• For intermediate-risk patients, the HR for NRM was 1.3 with HCT-CI versus 1.6 with MCI.
• For high-risk patients, the HR for NRM was 1.6 with HCT-CI versus 2.7 with MCI.

Conclusions:

• The modified comorbidity index (MCI) shows potential for higher discriminating and predictive power for overall survival and non-relapse mortality (NRM) in allogeneic HCT recipients.
• The MCI offers a more nuanced risk assessment by using hazard ratios for individual comorbidities.
• Further validation of the MCI in larger and independent HCT recipient cohorts is warranted.